SQLE

Squalene monooxygenase · Q14534 · SQLE on Sugi Atlas →

9,798 patent compounds predicted against SQLE, 6,379 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL408927)	0.98	20/20
Hydrochloric Acid (SCHEMBL408929)	0.98	20/20
SCHEMBL995860	0.50	9/20
Trisnorsqualene Alcohol (SCHEMBL2587282)	1.00	8/20
Trisnorsqualene Alcohol (SCHEMBL2587286)	1.00	8/20
Squalene (SCHEMBL15403)	0.81	8/20
Squalene (SCHEMBL15404)	0.81	8/20
SCHEMBL39067	0.81	8/20
Squalene (SCHEMBL890053)	0.81	8/20
Squalene (SCHEMBL1298145)	0.77	8/20
Squalene (SCHEMBL2515732)	0.77	8/20
Squalene (SCHEMBL2515736)	0.77	8/20
SCHEMBL295738	0.75	8/20
SCHEMBL295739	0.75	8/20
SCHEMBL1298146	0.74	8/20
SCHEMBL155871	0.68	8/20
SCHEMBL155872	0.68	8/20
SCHEMBL1716635	0.68	8/20
SCHEMBL1716636	0.68	8/20
SCHEMBL138766	0.68	8/20

Clinical trials — most relevant to SQLE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effects of Eicosapentaenoic Acid (EPA), Gamma-Linolenic Acid (GLA) and Antioxidants in the Treatment of Sepsis	PHASE4	COMPLETED
LDL Receptor Under Ezetimibe and Simvastatin	PHASE4	COMPLETED
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia	PHASE3	COMPLETED
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia	PHASE3	COMPLETED
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.	PHASE3	COMPLETED
Efficacy and Safety of Terbinafine and Itraconazole	PHASE2/PHASE3	UNKNOWN
Effect of Montelukast Versus Co Enzyme in Sepsis	PHASE2/PHASE3	COMPLETED
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia	PHASE2	COMPLETED
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis	PHASE2	COMPLETED
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis	PHASE2	WITHDRAWN
Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate	PHASE2	WITHDRAWN
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults	PHASE2	UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail	PHASE2	COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Effect of Topically Applied Olive Oil on Pruritus in Hemodialysis Patients: Pretest-posttest Model With Control Group	nan	COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors	nan	UNKNOWN
Dietary Intake of Whole Walnuts in Adult Subjects Under Low Cardiovascular Risk	nan	COMPLETED
Fatty Acid Regulation of Platelet Function in Diabetes	nan	COMPLETED
Eicosanoids in Human Heart Failure	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SQLE binder may also engage these)

Protein	Name	Similarity
P52019	—	0.998	P52019 →
P52020	—	0.994	P52020 →
Q9SM02	—	0.990	Q9SM02 →
Q42435	—	0.987	Q42435 →
Q43415	—	0.983	Q43415 →
Q38933	—	0.982	Q38933 →
B7TWW5	—	0.982	B7TWW5 →
Q9SEA0	—	0.982	Q9SEA0 →
Q40424	—	0.982	Q40424 →
Q9M424	—	0.981	Q9M424 →
Q43578	—	0.981	Q43578 →
O48651	—	0.980	O48651 →
I1RQ76	—	0.980	I1RQ76 →
Q75F69	—	0.980	Q75F69 →
Q9C8J4	—	0.979	Q9C8J4 →
Q43503	—	0.977	Q43503 →
P93236	—	0.977	P93236 →
O81000	—	0.976	O81000 →
Q43822	—	0.976	Q43822 →
Q9C8S9	—	0.976	Q9C8S9 →
Q8VYH2	—	0.976	Q8VYH2 →
K4C9E2	—	0.975	K4C9E2 →
Q5RH95	—	0.975	Q5RH95 →
Q92206	—	0.975	Q92206 →
Q8L5Z4	—	0.974	Q8L5Z4 →
Q6YXW6	—	0.974	Q6YXW6 →
Q9CQF9	—	0.974	Q9CQF9 →
Q8CFC1	—	0.973	Q8CFC1 →
Q43307	—	0.973	Q43307 →
P57681	—	0.973	P57681 →